BioSpace News Archive

The increase reflects the positive financial impact COVID-19 has had on the European diagnostic company’s bottom line.

Novartis plans to make the drugs available to government, non-governmental organizations (NGOs) and other institutional customers in up to 79 countries at no profit.

Wrapping up the month of July, there are three PDUFA dates on the U.S. Food and Drug Administration (FDA) calendar.

It was a surprisingly big week for clinical trial updates related to COVID-19, although there was plenty of non-COVID-19 news as well. Here’s a look.

The trendy drug brand names for 2020 include Tepezza®, Zolgensma®, and Qvar®. Like the names of newborn children, they are designed to be visually distinctive and to make a statement.

Rumors are flying that Paris-based Sanofi has a $50 billion budget for mergers and acquisitions and is taking a look at U.S.-based biotech companies. At the top of the list, reportedly, is South San Francisco-based Principia Biopharma.

Researchers at Australia’s Monash University have developed a test for SARS-CoV-2, the virus that causes COVID-19, that can provide results in 20 minutes.

Mirikizumab met all primary endpoints against placebo and secondary endpoints against Cosentyx in the Phase III study, the Indianapolis-based pharma company announced.

Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced the pricing of a $5.6 million offering, which consisted of an underwritten public offering of units and a private placement of units for gross proceeds of approximately $5.6 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the company. The public offering is compris

The virtual conference will include exceptional expert speakers, educational sessions, and participant meetups